Literature DB >> 22407409

PharmGKB summary: very important pharmacogene information for CYP3A5.

Jatinder Lamba1, Joan M Hebert, Erin G Schuetz, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22407409      PMCID： PMC3738061          DOI： 10.1097/FPC.0b013e328351d47f

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  54 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

Review 2.  Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.

Authors:  Kouichi Kurose; Emiko Sugiyama; Yoshiro Saito
Journal:  Drug Metab Pharmacokinet       Date:  2011-11-29       Impact factor: 3.614

3.  Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients.

Authors:  K Sailaja; D Nageswara Rao; D Raghunadha Rao; S Vishnupriya
Journal:  Asian Pac J Cancer Prev       Date:  2010

4.  Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension.

Authors:  Bo Xi; Chunyu Wang; Liu Liu; Tao Zeng; Yajun Liang; Jun Li; Jie Mi
Journal:  Hypertens Res       Date:  2011-08-04       Impact factor: 3.872

5.  Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.

Authors:  Jesus Garcia-Donas; Emilio Esteban; Luis Javier Leandro-García; Daniel E Castellano; Aranzazu González del Alba; Miguel Angel Climent; José Angel Arranz; Enrique Gallardo; Javier Puente; Joaquim Bellmunt; Begoña Mellado; Esther Martínez; Fernando Moreno; Albert Font; Mercedes Robledo; Cristina Rodríguez-Antona
Journal:  Lancet Oncol       Date:  2011-10-17       Impact factor: 41.316

6.  Dosing equation for tacrolimus using genetic variants and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

7.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.

Authors:  Akinbode Egbelakin; Michael J Ferguson; Emily A MacGill; Amalia S Lehmann; Ariel R Topletz; Sara K Quinney; Lang Li; Kevin C McCammack; Stephen D Hall; Jamie L Renbarger
Journal:  Pediatr Blood Cancer       Date:  2010-11-11       Impact factor: 3.167

8.  Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.

Authors:  D Krishnakumar; Umamaheswaran Gurusamy; Kayathri Dhandapani; A Surendiran; Ruchi Baghel; Ritushree Kukreti; Reneega Gangadhar; Ushakiran Prayaga; S Manjunath; C Adithan
Journal:  Fundam Clin Pharmacol       Date:  2011-01-25       Impact factor: 2.748

9.  The genetic determinants of the CYP3A5 polymorphism.

Authors:  E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski
Journal:  Pharmacogenetics       Date:  2001-12

10.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

Authors:  Yvonne S Lin; Amy L S Dowling; Sean D Quigley; Federico M Farin; Jiong Zhang; Jatinder Lamba; Erin G Schuetz; Kenneth E Thummel
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436
View more
  41 in total

1.  Clinical Pharmacogenomics: Applications in Nephrology.

Authors:  Solomon M Adams; Karryn R Crisamore; Philip E Empey
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 8.237

Review 2.  Combinations of chromosome transfer and genome editing for the development of cell/animal models of human disease and humanized animal models.

Authors:  Narumi Uno; Satoshi Abe; Mitsuo Oshimura; Yasuhiro Kazuki
Journal:  J Hum Genet       Date:  2017-11-27       Impact factor: 3.172

3.  The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome.

Authors:  Janet K Coller; Jeyamani Ramachandran; Libby John; Jonathan Tuke; Alan Wigg; Matthew Doogue
Journal:  Br J Clin Pharmacol       Date:  2019-07-24       Impact factor: 4.335

Review 4.  Transplant genetics and genomics.

Authors:  Joshua Y C Yang; Minnie M Sarwal
Journal:  Nat Rev Genet       Date:  2017-03-13       Impact factor: 53.242

5.  Rapid screening for targeted genetic variants via high-resolution melting curve analysis.

Authors:  Allison B Chambliss; Molly Resnick; Athena K Petrides; William A Clarke; Mark A Marzinke
Journal:  Clin Chem Lab Med       Date:  2017-03-01       Impact factor: 3.694

6.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

7.  Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy.

Authors:  Sharmila Das; Dong Guo; Xiaohui Jiang; Wenlei Jiang; Yan Shu; Tricia Y Ting; James E Polli
Journal:  Pharm Res       Date:  2020-02-26       Impact factor: 4.200

Review 8.  Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.

Authors:  Karla Claudio-Campos; Jorge Duconge; Carmen L Cadilla; Gualberto Ruaño
Journal:  Drug Metab Pers Ther       Date:  2015-06

9.  Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.

Authors:  Matthew Oetjens; William S Bush; Kelly A Birdwell; Holli H Dilks; Erica A Bowton; Joshua C Denny; Russell A Wilke; Dan M Roden; Dana C Crawford
Journal:  Pac Symp Biocomput       Date:  2014

10.  Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

Authors:  R Franca; P Rebora; N Bertorello; F Fagioli; V Conter; A Biondi; A Colombini; C Micalizzi; M Zecca; R Parasole; F Petruzziello; G Basso; M C Putti; F Locatelli; P d'Adamo; M G Valsecchi; G Decorti; M Rabusin
Journal:  Pharmacogenomics J       Date:  2015-12-08       Impact factor: 3.550
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.